
News|Articles|November 15, 2012
Sanofi lowers price of Zaltrap after Sloan-Kettering refusal to use it
Sanofi is lowering the price of ziv-aflibercept (Zaltrap) for previously treated colorectal cancer by half after physicians at Memorial Sloan Kettering Cancer Center (MSKCC) said that they would not use the drug, according to The New York Times.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
CGM prescribed by primary care lowers A1C and acute care use in diabetes patients
3
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
4
Could uveitis in patients with melanoma being treated with immune checkpoint inhibitors be a good thing?
5


























